C4 Therapeutics Showcases Progress on IKZF1/3 Degrader and Expanding Protein Degradation Pipeline
C4 Therapeutics Inc. has updated its clinical and preclinical pipeline, focusing on targeted protein degradation therapies. The company is advancing cemsidomide, an IKZF1/3 degrader, with completed Phase 1 trials in multiple myeloma and plans for Phase 2 trials. Upcoming data presentations are expected for non-Hodgkin’s lymphoma and multiple myeloma studies. Additionally, C4 is developing CFT8919 for EGFR L858R mutations and CFT1946 for BRAF V600 mutant tumors, while collaborating with Roche and MKDG. The company aims to leverage its decade of experience in protein degradation for various oncology and non-oncology applications.
C4 Therapeutics Inc. has provided an update on its clinical and preclinical pipeline, highlighting progress in targeted protein degradation therapies. The company is advancing cemsidomide, an IKZF1/3 degrader, with completed Phase 1 dose escalation in multiple myeloma (MM) and ongoing plans for Phase 2 trials in combination with dexamethasone. Data from Phase 1 studies in non-Hodgkin’s lymphoma (NHL) and MM are expected to be presented at upcoming medical meetings. C4 Therapeutics also continues development of CFT8919 targeting EGFR L858R mutations and CFT1946 for BRAF V600 mutant solid tumors, while progressing early-stage programs through collaborations with Roche and MKDG. The company is building on a decade of experience in protein degradation to address a range of oncology and non-oncology indications. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
